A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509 a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist in Adult Patients With Advanced Solid Tumors
This is a Phase 1, open label, multi-center study of intravenously administered DSP-0509 in adult subjects with advance solid tumors that are refractory to standard treatment.
The study consists of two stages: an initial dose escalation phase utilizing a 3 + 3 design to determine maximum tolerated dose followed by a dose expansion phase in up to 14 additional subjects. Study participants will initially receive DSP-0509 intravenously once a week in induction phase, and once every two weeks in a maintenance phase. If clinical benefit is seen, treatment can continue until disease progression.
Participants will not be paid for their participation.
- IRB Number: 1804027965 (BBI-DSP0509-101)
- Research Study Identifier: TX8859
- Principal Investigator: Shadia Jalal, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required